TORNTPHARM · Torrent Pharmaceuticals Ltd · Biotechnology & Drugs
TORNTPHARM · Torrent Pharmaceuticals Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
9.5% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹4,921 Cr
Revenue YoY
PAT YoY
+3.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
Not available from data source
P/S (TTM)
12
Sector P/E
36.3
Dividend yield
+0.8%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| TORNTPHARM (this stock) | 73.8 | Not available from data source | +13.9% | +26.0% | 1.79 | +0.8% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Cipla | 35.1 | 4 | +11.9% | +9.8% | 0.02 | +0.9% |
Promoter
falling 1q
FII
rising 1q
MF
8.27% (+3.33pp)
rising 2q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 06 Feb 2026 | Geena Malhotra | BUY | 100 | ₹3.94 lakh |
| 06 Feb 2026 | Geena Malhotra | BUY | 100 | ₹3.94 lakh |
| 01 Feb 2026 | Geena Malhotra | BUY | 200 | ₹8.01 lakh |
| 01 Feb 2026 | Geena Malhotra | BUY | 200 | ₹8.01 lakh |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: The document provides a notice regarding the availability of the transcript for Torrent Pharmaceuticals Limited's conference call discussing financial results for the quarter and half year ended 30 September 2026. The transcript is accessible on the company's website at the provided link. The notice was sent to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) on 29 October 2026, fulfilling regulatory disclosure requirements under SEBI regulations. The document does not include the actual content of the conference call or specific financial results, guidance, or management commentary from the call itself.
The tone is neutral as the document is a routine regulatory disclosure notice without forward-looking statements or evaluative language.
Sourced from an exchange-filed transcript, dated 29 Oct 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The document is a communication from Torrent Pharmaceuticals Limited regarding the transcript of a discussion with analysts and investors about the financial results for the quarter ended 30th June 2026. It references a previous letter dated 17th July 2026 and states that the transcript has been made available on the company's website. The communication is signed by Chintan M. Trivedi, the Company Secretary, and includes details for the BSE and NSE listing codes. The document serves to inform stakeholders about the availability of the financial results discussion transcript.
The document provided factual information regarding the availability of the transcript.
Sourced from an exchange-filed transcript, dated 04 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The document is a communication from Torrent Pharmaceuticals Limited to the stock exchanges regarding the transcript of a conference call with analysts and investors. This call discussed the audited financial results for the quarter and year ended 31st March 2026. The company referenced previous letters dated 12-May-26 and 16-May-26 and noted that the transcript has been made available on the company's website. The communication was signed by Chintan M. Trivedi, the Company Secretary.
The document presented factual information regarding the conference call and the availability of the transcript.
Sourced from an exchange-filed transcript, dated 27 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation reported on the audited financial results for Torrent Pharmaceuticals Limited for the quarter and year ended March 31, 2026. For Q4 FY 2025-26, the company achieved total revenues of Rs 2,215 crore, reflecting a growth of 43% compared to the previous year. Revenue contributions came from various regions, with India growing by 31% to Rs 396 crore, the United States by 16% to Rs 333 crore, Germany by 30% to Rs 455 crore, Brazil by 68% to Rs 798 crore, and other regions by 42%. For the full fiscal year 2025-26, total revenues reached Rs 13,980 crore, a 21% increase from the prior year, with notable growth in India (20%), the United States (24%), Germany (10%), Brazil (24%), and others (32%).
The presentation highlighted significant revenue growth across multiple regions.
Sourced from an exchange-filed presentation, dated 22 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The document is a communication from Torrent Pharmaceuticals Limited regarding the transcript of a conference call with analysts and investors. This call discussed the financial results for the quarter and nine months ended December 31, 2025. The company provided a link to the transcript on its website and referenced a previous letter dated February 2, 2026, in accordance with SEBI regulations. The communication was signed by Chintan M. Trivedi, the Company Secretary.
The document presented factual information regarding the conference call and financial results.
Sourced from an exchange-filed transcript, dated 20 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation reported the unaudited consolidated financial results for Torrent Pharmaceuticals Limited for the quarter and nine months ended 31st December 2025. For Q3 FY26, the total revenue reached Rs 3,303 crore, reflecting an 18% increase from Rs 2,809 crore in Q3 FY25. Revenue growth was noted across various regions, with India growing by 14% to Rs 1,798 crore, the United States by 19% to Rs 321 crore, Germany by 8% to Rs 304 crore, Brazil by 27% to Rs 371 crore, and other regions by 32% to Rs 509 crore. Year-to-date figures showed total revenue of Rs 9,783 crore, a 14% increase from Rs 8,557 crore in the previous year, with notable growth in India (12%), the United States (21%), Germany (7%), Brazil (21%), and other regions (20%).
Management reported strong revenue growth across multiple regions.
Sourced from an exchange-filed presentation, dated 13 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedTorrent Pharmaceuticals Limited reported a 15% increase in net profit to ₹1,911 crores for FY2024-25, driven by a 7% rise in consolidated sales and a 10% growth in operating EBITDA. The company addressed a long-standing NPPA demand related to alleged overcharging, reducing legal exposure through a settlement. The auditor noted key audit matters including impairment testing of goodwill and revenue recognition practices, with no material misstatements identified. The company maintains robust compliance with legal and regulatory requirements, with no material defaults or penalties reported.
- Net profit increased by 15% to ₹1,911 crores in FY2024-25.
- Consolidated sales grew by 7% to ₹11,516 crores.
- Settled NPPA demand, reducing legal exposure from 2017 allegations.
- Auditor highlighted impairment testing of goodwill and revenue recognition as key audit matters.
Key takeaway: Torrent Pharmaceuticals delivered strong financial performance with improved profitability and resolved a significant legal issue, though ongoing audit and regulatory considerations remain important to monitor.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
A pending complaint related to Curatio Health Care (I) Private Limited was transferred to the Company following its merger as per the National Company Law Tribunal's order dated 17th May, 2023.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
The company has undisputed statutory dues in arrears for more than six months as of 31 March 2024, specifically related to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs, or Cess.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The Group has assumed all the contingent liabilities of JBCPL amounting to ₹47.72 crores.
Earlier (1-3 years ago)
The company has net guarantees given for ₹23.17 crores in respect of subsidiaries for 2024-25.
The company has net guarantees given for 2023-24 amounting to ₹12.15 crores in respect of subsidiaries.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has transactions with related parties, including sales of finished goods to Torrent Pharma Inc., Torrent Do Brasil Ltda., Heumann Pharma GmbH & Co. Generica KG, Zao Torrent Pharma, Torrent Pharma Philippines, Inc., Laboratories Torrent (Malaysia) Sdn. Bhd., and Laboratorios Torrent S.A. de C.V., amounting to 2,274.91 crores in 2025-26.
Earlier (1-3 years ago)
The company disclosed related-party transactions involving the sale of finished goods to Torrent Pharma Inc. for 897.13 crores in 2024-25 and 1,868.52 crores in 2023-24.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of any dispute.
Earlier (1-3 years ago)
The company has disputes over Goods and Service Tax, Service Tax, and other statutory dues, with amounts involved pending before CESTAT and the Supreme Court of India.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
0.27% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).